Filing Flows › Regenxbio (RGNX) › Q1 2026
Regenxbio (RGNX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Regenxbio (RGNX) reported revenue of $6.4M for the first quarter 2026 (Q1 2026), -93% from a year earlier and -79% from the quarter before.
Regenxbio, Q1 2026: revenue $6.4M (-93% year over year), net loss $90.1M, operating cash flow −$76.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.4M | -79% | -93% |
| Operating profit | −$83.4M | — | -787% |
| Net earnings | −$90.1M | — | -1580% |
| Operating cash flow | −$76.2M | — | -327% |
What changed
Revenue was $6.4M in Q1 2026, down 93% year over year and down 79% from the previous quarter. License and Service was the largest line at 80% of revenue. License and Service lost $82.0M year over year (down 94%), 99% of the total change.
Operating costs exceeded revenue by $83.4M, an operating margin of -1304.0%. Total costs grew 17% against a revenue fall of 93%. The fastest-growing cost line was Other operating costs (+222%). The quarter ended with a net loss of $90.1M, wider than the previous quarter's $67.1M loss.
Operating cash flow was −$76.2M. Non-cash charges added back $3.9M of depreciation and amortization and $8.6M of share-based compensation. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$77.4M.
Questions
What was Regenxbio's revenue in the first quarter 2026?
Regenxbio (RGNX) reported revenue of $6.4M for the first quarter 2026 (Q1 2026), -93% from a year earlier and -79% from the quarter before.
Source: Regenxbio 10-Q on SEC EDGAR.